Clinical Research Directory
Browse clinical research sites, groups, and studies.
Palmitoylethanolamide in Ulcerative Colitis
Sponsor: Ain Shams University
Summary
Evaluate the effects of PEA supplementation on disease activity, health-related quality of life (HRQoL) and inflammatory biomarkers in patients with active mild-to-moderate UC.
Official title: The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2026-07-15
Completion Date
2029-02-15
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Interventions
Palmitoylethanolamide (PEA)
Palmitoylethanolamide (PEA) is an endocannabinoid-like bioactive lipid mediator which belongs to the family of N-acylethanolamine (NAE) fatty acid amides. It exerts anti-inflammatory, antioxidant, antimicrobial, analgesic, immunomodulatory and neuroprotective actions through acting at different sites like: PPAR-α, G-protein coupled receptor 55 (GPR55), cannabinoid receptors 1 and 2 (CB1 and CB2) and transient receptor potential vanilloid receptor 1 (TRPVR1) channels. PEA is a commercially available supplement mainly used to alleviate chronic neuropathic pain and persistent musculoskeletal pain. PEA has proven to be safe and tolerable across multiple studies with very rare cases reporting mild side effects like: intermittent headache, nausea, constipation, urticaria and fatigue. It will be given in this study at a dose of 600 mg/day
Locations (1)
Internal Medicine and Gastroenterology clinic, El-Demerdash Hospital
Cairo, El-Abbasia, Egypt